Table 2.
Table 2a. Prechemotherapy clinical versus pathologic stage of the primary tumor at cystectomy in gemcitabine-cisplatin cohort for all patients irrespective of the dosing schedule (N=42) | |||||||
---|---|---|---|---|---|---|---|
Pre-Chemotherapy Clinical Stage | Pathologic Stage at Cystectomy |
||||||
pT0 | pTIS | pT1 | pT2 | pT3 | pT4 | Total | |
cT2 | 5 | 1 | 1 | 4 | 7 | 1 | 19 |
cT3 | 5 | 1 | 1 | 5 | 7 | 0 | 19 |
cT4 | 1 | 0 | 0 | 0 | 3 | 0 | 4 |
Total | 11 | 2 | 2 | 9 | 17 | 1 | 42 |
Table 2b. Clinical versus pathologic stage of the primary tumor at cystectomy in the gemcitabine-cisplatin cohort according to dosing schedule | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Dosing Regimen | Pathologic Stage at Cystectomy |
||||||||||
≤ pT1 | pT2 | pT3 | pT4 | Total | |||||||
Split dose | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | |
cT2 | 0 | 7 | 2 | 2 | 5 | 2 | 0 | 0 | 7 | 12 | |
cT3 | 2 | 5 | 1 | 4 | 2 | 5 | 0 | 0 | 5 | 14 | |
cT4 | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 1 | 3 | 1 | |
Total | 2 | 13 | 3 | 6 | 10 | 7 | 0 | 1 | 15 | 27 |